Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Adult acute myeloid leukemia with NUP98 rearrangement benefits from targeted therapy and bone marrow transplantation

Blood (2025) 146 (Supplement 1): 3391.

https://doi.org/10.1182/blood-2025-3391

Published: 2025

Journal Articles

Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study

Blood (2025) 146 (Supplement 1): 5182.

https://doi.org/10.1182/blood-2025-5182

Published: 2025

Journal Articles

Efficacy and safety of a fully human BCMA CAR T-cell therapy for high-risk newly diagnosed transplant-ineligible multiple myeloma: Updated results from an open label, single-arm，phase 1 study（fumanba-2）

Bing Chen, Xiaoyan Shao, Yuanyuan Jin, Yong Xu, Qinglin Shi, Chaoyang Guan, Xuxing Shen, Ping Li, Yujie Wu, Hui Zeng, Yu Zhu, Min Zhou, Lei Fan, Yaqiong Lu, Hongyu Gui, Lijuan Chen

Blood (2025) 146 (Supplement 1): 254.

https://doi.org/10.1182/blood-2025-254

Published: 2025

Journal Articles

Construction and evaluation of a prognostic model for patients with Acute Myeloid Leukemia

Feng Zhu, Yile Zhou, Yi Zhang, Liping Mao, Yinjun Lou, Yu Zhu, Zheng Ge, Zhiyong Zeng, Fengbo Jin, Tingting Liu, Haitao Xu, Yue Yao, Quanyi Lu, Jianxin Guo, Hongyan Tong, Huafeng Wang, Jie Jin

Blood (2025) 146 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2025-1728

Published: 2025

Journal Articles

Benchmark evaluation of large language models in acute myeloid leukemia prognosis

Xiangjie Lin, Di Xu, Nanfang Zhuo, Jingrui Jin, Yujia Wang, Liping Mao, Yinjun Lou, Min Yang, Haitao Meng, Wanzhuo Xie, Jian Huang, Hongyan Tong, Shengli Xue, Yu Zhu, Jie Jin, Jun Wang, Huafeng Wang

Blood (2025) 146 (Supplement 1): 7954.

https://doi.org/10.1182/blood-2025-7954

Published: 2025

Journal Articles

Preclinical and clinical Study of olverembatinib in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement

Blood (2025) 146 (Supplement 1): 1979.

https://doi.org/10.1182/blood-2025-1979

Published: 2025

Journal Articles

Characterisation of the megakaryocyte proteome in patients with Philadelphia negative myeloproliferative neoplasms

Indu Raman, Cavan Bennett, Anne Pettikiriarachchi, Ricardo Ataide, Yu Zhu, Ellen Tsui, Surender Juneja, Samantha Emery-Corbin, Sukhdeep Spall, Jumana Yousef, Laura Dagley, Costas Yannakou, Sant-Rayn Pasricha

Blood (2025) 146 (Supplement 1): 5539.

https://doi.org/10.1182/blood-2025-5539

Published: 2025

Journal Articles

Characteristics and clinical outcomes of ND-AML patients with bcor/bcorl1 mutations

Blood (2025) 146 (Supplement 1): 7005.

https://doi.org/10.1182/blood-2025-7005

Published: 2025

Journal Articles

Treatment-free remission outcomes in pediatric chronic myeloid leukemia: Second-generation TKIs vs. Imatinib–a real-world multicenter study from China

HUIFANG ZHAO, Yu Zhu, Na Xu, QINGSHU ZENG, Shuxia Guo, Li xin Liang, Bingcheng LIU, Weiming Li, Qian Jiang, Yanli Zhang

Blood (2025) 146 (Supplement 1): 3786.

https://doi.org/10.1182/blood-2025-3786

Published: 2025

Journal Articles

Real-world effectiveness and safety of gilteritinib plus venetoclax and azacitidine in FLT3 mutated acute myeloid leukemia

Nianci Chen, Yu Zhu, Zhenqi Huang, Ying Lu, Yinjun Lou, Liping Mao, Xinping Zhou, Dan Chen, Lihong Shou, Huang Li, Cuihua Fan, Hongyan Tong, Jie Jin, Huafeng Wang, East China Leukemia Alliance (Ecla)

Blood (2025) 146 (Supplement 1): 5237.

https://doi.org/10.1182/blood-2025-5237

Published: 2025

Journal Articles

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Blood (2024) 144 (Supplement 1): 4529.

https://doi.org/10.1182/blood-2024-203533

Published: 2024

Journal Articles

Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Fang Cheng, Yu Wang, Xin Du, Yu Zhu, Jianyu Weng, Na Xu, Yunfan Yang, Jian Huang, Zhenfang Liu, Hongbo Ren, Huifang Zhao, Yajuan Ke, Weiyan Wu, Huanling Zhu, Qian Jiang, Yanli Zhang, Weiming Li

Blood (2024) 144 (Supplement 1): 4540.

https://doi.org/10.1182/blood-2024-202876

Published: 2024

Journal Articles

A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement

Suning Chen, Depei Wu, Wenzhi CAI, Xueqing Dou, Zhenfang Liu, Yu Zhu, Ying Wang, Chunmei Yang, Jiong Hu, Miao Miao, Xiuzhi Deng, Chunyan Chen

Blood (2024) 144 (Supplement 1): 1781.

https://doi.org/10.1182/blood-2024-200003

Published: 2024

Journal Articles

Tigit: The Potential Mechanisms of Relapse in Multiple Myeloma Following Anti-BCMA CAR-T Therapy and a Promising Target for Improving CAR-T Efficacy

Yuan Xia, Xuxing Shen, Min Shi, Na Shen, Yu Zhu, Lei Fan, Jianyong Li, Lijuan Chen

Blood (2024) 144 (Supplement 1): 2033.

https://doi.org/10.1182/blood-2024-205126

Published: 2024

Journal Articles

Update Results of a Phase II Trial of Venetoclax in Combination with Azacitidine and Chidamide in Relapsed/Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4274.

https://doi.org/10.1182/blood-2023-182832

Published: 2023

Journal Articles

Relationship between Sarcopenia and the Heterogeneity and Microenvironment of Acute Myeloid Leukemia Based on Single-Cell Transcriptome Sequencing

Qian Sun, Wenjie Liu, Ming Hong, Yu Zhu, Jianyong Li, Sixuan Qian

Blood (2023) 142 (Supplement 1): 6026.

https://doi.org/10.1182/blood-2023-173220

Published: 2023

Journal Articles

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2023-179073

Published: 2023

Journal Articles

Preclinical Studies and Phase II Trial of Venetoclax in Combination with Chidamide and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 3292–3293.

https://doi.org/10.1182/blood-2022-165261

Published: 2022

Journal Articles

The Decrease of Anti-CD3 Antibody Concentration Improved the Cytotoxicity of Chimeric Antigen Receptor (CAR) T Cells in the Treatment of Chronic Lymphoblastic Leukemia (CLL)

Sanmei Wang, Yilian Yang, Yu Zhu, Lei Fan, Michael Schmitt, Maria Luisa Schubert, Jianyong Li

Blood (2021) 138 (Supplement 1): 4792.

https://doi.org/10.1182/blood-2021-150661

Published: 2021

Journal Articles

The Prognosis of Intermediate- and High-Risk Young AML Patients Who Did Not Receive Allo-HSCT Treated with Intensive Chemotherapy Is Not Superior to That of Elderly AML Patients Treated with the D-CAG Regimen

Ming Hong, Qian Sun, Wenjie Liu, Han Zhu, Yu Zhu, Jianyong Li, Sixuan Qian

Blood (2021) 138 (Supplement 1): 1228.

https://doi.org/10.1182/blood-2021-149060

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Adult acute myeloid leukemia with NUP98 rearrangement benefits from targeted therapy and bone marrow transplantation

Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study

Efficacy and safety of a fully human BCMA CAR T-cell therapy for high-risk newly diagnosed transplant-ineligible multiple myeloma: Updated results from an open label, single-arm，phase 1 study（fumanba-2）

Construction and evaluation of a prognostic model for patients with Acute Myeloid Leukemia

Benchmark evaluation of large language models in acute myeloid leukemia prognosis

Preclinical and clinical Study of olverembatinib in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement

Characterisation of the megakaryocyte proteome in patients with Philadelphia negative myeloproliferative neoplasms

Characteristics and clinical outcomes of ND-AML patients with bcor/bcorl1 mutations

Treatment-free remission outcomes in pediatric chronic myeloid leukemia: Second-generation TKIs vs. Imatinib–a real-world multicenter study from China

Real-world effectiveness and safety of gilteritinib plus venetoclax and azacitidine in FLT3 mutated acute myeloid leukemia

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement

Tigit: The Potential Mechanisms of Relapse in Multiple Myeloma Following Anti-BCMA CAR-T Therapy and a Promising Target for Improving CAR-T Efficacy

Update Results of a Phase II Trial of Venetoclax in Combination with Azacitidine and Chidamide in Relapsed/Refractory Acute Myeloid Leukemia

Relationship between Sarcopenia and the Heterogeneity and Microenvironment of Acute Myeloid Leukemia Based on Single-Cell Transcriptome Sequencing

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Preclinical Studies and Phase II Trial of Venetoclax in Combination with Chidamide and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

The Decrease of Anti-CD3 Antibody Concentration Improved the Cytotoxicity of Chimeric Antigen Receptor (CAR) T Cells in the Treatment of Chronic Lymphoblastic Leukemia (CLL)

The Prognosis of Intermediate- and High-Risk Young AML Patients Who Did Not Receive Allo-HSCT Treated with Intensive Chemotherapy Is Not Superior to That of Elderly AML Patients Treated with the D-CAG Regimen

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only